INPPL1 and type 2 diabetes mellitus: Identification of metformin as a SHIP2 inhibitor and the findings described above, indicating that SHIP2 inhibition improves glucose metabolism, indicate that SHIP2 is an excellent target to design new treatments to ameliorate insulin resistance and T2D.